13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CHPF Regulates the Aggressive Phenotypes of Hepatocellular Carcinoma Cells via the Modulation of the Decorin and TGF-β Pathways

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Simple Summary

          Altered extracellular chondroitin sulfate (CS) contributes to tumor progression in many cancers. CHPF is a key enzyme supporting the elongation of CS. Here we showed that CHPF was frequently downregulated in hepatocellular carcinoma (HCC) tumors compared with adjacent non-tumor tissues, and its downregulation was associated with poor overall survival. CHPF regulated aggressive phenotypes of HCC cells in vitro and in vivo, and the TGF-β pathway involved in the phenotypical changes. Mechanistically, CHPF modified CS on decorin (DCN), which could facilitate DCN accumulation surrounding HCC cells, and modulate activation of TGF-β pathway. Indeed, the expression of DCN were positively associated with CHPF levels in primary HCC tissue. The research proposed novel insights into the significance of CHPF, which modified DCN and modulated TGF-β signaling.

          Abstract

          Aberrant composition of glycans in the tumor microenvironment (TME) and abnormal expression of extracellular matrix proteins are hallmarks of hepatocellular carcinoma (HCC); however, the mechanisms responsible for establishing the TME remain unclear. We demonstrate that the chondroitin polymerizing factor (CHPF), an enzyme that mediates the elongation of chondroitin sulfate (CS), is a critical elicitor of the malignant characteristics of HCC as it modifies the potent tumor suppressor, decorin (DCN). CHPF expression is frequently downregulated in HCC tumors, which is associated with the poor overall survival of HCC patients. We observed that restoring CHPF expression suppressed HCC cell growth, migration, and invasion in vitro and in vivo. Mechanistic investigations revealed that TGF-β signaling is associated with CHPF-induced phenotype changes. We found that DCN, as a TGF-β regulator, is modified by CHPF, and that it affects the distribution of DCN on the surface of HCC cells. Importantly, our results confirm that CHPF and DCN expression levels are positively correlated in primary HCC tissues. Taken together, our results suggest that CHPF dysregulation contributes to the malignancy of HCC cells, and our study provides novel insights into the significance of CS, which affects DCN expression in the TME.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular mechanisms of epithelial-mesenchymal transition.

          The transdifferentiation of epithelial cells into motile mesenchymal cells, a process known as epithelial-mesenchymal transition (EMT), is integral in development, wound healing and stem cell behaviour, and contributes pathologically to fibrosis and cancer progression. This switch in cell differentiation and behaviour is mediated by key transcription factors, including SNAIL, zinc-finger E-box-binding (ZEB) and basic helix-loop-helix transcription factors, the functions of which are finely regulated at the transcriptional, translational and post-translational levels. The reprogramming of gene expression during EMT, as well as non-transcriptional changes, are initiated and controlled by signalling pathways that respond to extracellular cues. Among these, transforming growth factor-β (TGFβ) family signalling has a predominant role; however, the convergence of signalling pathways is essential for EMT.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Hepatocellular carcinoma.

            Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Patients with cirrhosis are at highest risk of developing this malignant disease, and ultrasonography every 6 months is recommended. Surveillance with ultrasonography allows diagnosis at early stages when the tumour might be curable by resection, liver transplantation, or ablation, and 5-year survival higher than 50% can be achieved. Patients with small solitary tumours and very well preserved liver function are the best candidates for surgical resection. Liver transplantation is most beneficial for individuals who are not good candidates for resection, especially those within Milano criteria (solitary tumour ≤5 cm and up to three nodules ≤3 cm). Donor shortage greatly limits its applicability. Percutaneous ablation is the most frequently used treatment but its effectiveness is limited by tumour size and localisation. In asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread not amenable to curative treatments, chemoembolisation can provide survival benefit. Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma, suggesting that molecular-targeted therapies could be effective in this chemoresistant cancer. Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma. Copyright © 2012 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?

                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Cancers (Basel)
                Cancers (Basel)
                cancers
                Cancers
                MDPI
                2072-6694
                12 March 2021
                March 2021
                : 13
                : 6
                : 1261
                Affiliations
                [1 ]Department of Anatomy, Faculty of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; chiung@ 123456csmu.edu.tw (C.-H.L.); s0701009@ 123456gm.csmu.edu.tw (B.-R.W.); yinhung@ 123456csmu.edu.tw (Y.-H.C.); s0801044@ 123456gm.csmu.edu.tw (W.-C.H.); tjtseng@ 123456csmu.edu.tw (T.-J.T.)
                [2 ]Department of Medical Education, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
                [3 ]Department of Psychology, Chung Shan Medical University, Taichung 40201, Taiwan; yjho@ 123456csmu.edu.tw
                [4 ]Department of Pathology, Faculty of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
                [5 ]Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
                Author notes
                [* ]Correspondence: jupili@ 123456csmu.edu.tw (J.-P.L.); aliceliudog@ 123456gmail.com (W.-C.L.); Tel.: +886-4-24730022 (ext. 21756) (J.-P.L.); +88642-2473-0022 (ext. 11610) (W.-C.L.)
                Author information
                https://orcid.org/0000-0003-3406-4865
                Article
                cancers-13-01261
                10.3390/cancers13061261
                8002199
                33809195
                4aacc922-858e-4331-8d1a-ca2a379bca34
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 24 February 2021
                : 10 March 2021
                Categories
                Article

                hepatocellular carcinoma,tumor microenvironment,chondroitin polymerizing factor,chondroitin sulfate,decorin

                Comments

                Comment on this article